Related by context. All words. (Click for frequent words.) 67 Consensus Statement 65 Position Paper 65 Clinical Practice Guideline 64 Guidance Document 62 Practice Guideline 61 Preliminary Findings 60 Expert Advisory Panel 59 NCCN Drugs 59 Clinical Guideline 59 Clinical Practice Guidelines 58 Final Appraisal Determination 58 NCCN Drugs & 58 #-# Full Text 57 SHIRE PLC 57 Hazardous Drugs 57 Emphasizes Need 57 Guideline Update 57 Proposed Revisions 57 SmPC 57 Product Monograph 57 Issue Brief 57 Recommended Practices 57 Combating Counterfeit Drugs 57 Study Shows Benefits 56 Musculo Skeletal Disorders 56 Guidelines Issued 56 Appropriateness Criteria 56 Consultation Document 56 Best Practice Guidelines 56 Proposed Changes 56 Peer Reviewed Journal 56 Analytical Methods 56 Regulatory Toxicology 56 Guideline 56 Resale Registration Statement 56 #:#-# [006] 56 Seasonal Influenza Vaccine 56 Ethical Considerations 56 Proposed Rule Changes 56 PhRMA Code 56 Biologics Compendium 56 Reduces Mortality 55 Issues Relating 55 Expedited Review 55 #:#-# [019] 55 Osteoarthritis Patients 55 Investigational Drugs 55 Improving Outcomes 55 Treating Chronic 55 Resubmission 55 Randomized Controlled Trials 55 Specification PAS 55 Pharmacopeial Convention 55 Cardiovascular Interventions 55 Package Insert 55 Clinical Efficacy 55 #:#-#,# Medline 55 Regulatory Developments 55 Multidisciplinary Approach 55 Stakeholder Meeting 55 Biological Effects 55 Dietary Reference Intakes 55 Filing Status 54 NCCN Clinical Practice Guidelines 54 journal Arteriosclerosis Thrombosis 54 Concise Guide 54 Homosexual Persons 54 Recommends Changes 54 Clinical Trial Data 54 Issues Guidance 54 SCENIHR 54 Clinical Evaluation 54 Applauds Introduction 54 Proxy Proposals 54 Spinal Manipulation 54 GRAS Status 54 Schizophrenia Treatment 54 Shareholder Letter 54 Differential Diagnosis 54 Alternative Treatments 54 Toxicity Testing 54 National Coverage Determination 54 Ultrasound Guided 54 Issues Clarification 54 Endocrine Practice 54 Periodontal Disease 54 #:# -# [003] 54 Statement 54 Concluding Observations 54 #:#-# [040] 54 Gastrointestinal Disorders 54 #:#-# Abstract Free [003] 54 Drug Approvals 54 #:#-#,# CrossRef Medline [002] 54 Unanimously Recommends 53 Approvable 53 Vaccine Immunology 53 Molecular Cancer 53 Issues Surrounding 53 Improve Diagnosis 53 Voluntary Guidelines 53 Citizen Petition 53 ACCF AHA 53 Product Characteristics 53 Environmental Impacts 53 Guidelines Recommend 53 Successful Outcome 53 Childhood Vaccinations 53 #:#-#,# [003] 53 Legislative Priorities 53 Panel Faults 53 Elects Officers 53 Governance Structure 53 Receives Favorable 53 Product Labeling 53 explanatory memoranda 53 Informational Seminar 53 Acne Drug 53 Electronic Prescribing 53 Childhood Overweight 53 Arch Dermatol 53 Increased Incidence 53 Preventing Medication Errors 53 Childhood Vaccines 53 Respirology 53 PDUFA Date 53 Patent Reexamination 53 Balanced Approach 53 #:#-#,# Abstract Free 53 Ethical Guidelines 53 Urine Test 53 Program NCEP 53 Proposed Regulations 53 entitled Formulary Advantages 53 article #.#/NEJMoa# 53 Contraceptive Use 53 Prehospital Emergency Care 53 Metabolic Disorder 53 Interpretive Guidance 53 See WARNINGS 53 Pesticide Residues 53 License Application 53 Devices Advisory Panel 53 Am J Epidemiol 53 Skin Infections 53 #:#-#,# [002] 53 Approval Process 53 theAmerican Journal 53 Counterparty Criteria 53 Arthritis Drugs 53 Systematic Reviews 53 Preterm Labor 53 EXPLANATORY STATEMENT 53 BENECOL R Spreads 52 Webinar Focuses 52 Metabolic Endocrinology 52 Clinician Guide 52 Female Urology 52 Late Breaker 52 Diet Supplement 52 Issues Shareholder 52 Therapy Reduces 52 Fact Sheet 52 Laryngeal Cancer 52 Comment Period 52 First Patient Enrolled 52 #:# -# [004] 52 Therapeutic Intervention 52 Report EIR 52 Notice Regarding 52 Therapeutic Approaches 52 Therapeutic Potential 52 Colorectal Screening 52 Statement EIS 52 CHMP Opinion 52 Ethnic Disparities 52 Systematic Review 52 Quadrivalent 52 peer reviewed journal Annals 52 Screening Mammography 52 Data Suggest 52 ISSN #-# 52 Fee Schedule 52 Medication Errors 52 Recommended Practice 52 Pharmacoepidemiology 52 Data Sheet 52 Stable Angina 52 Accessed #/#/# [001] 52 Guidelines 52 Unapproved Drugs 52 NIH Publication 52 Computed Tomographic 52 Unsolicited Proposal From 52 Recommends Approval 52 #:#-# Abstract Free [008] 52 Mitigation Strategy 52 Inflammatory Pain 52 Prospective Randomized 52 Waiver Request 52 assn.org 52 Submits NDA 52 FDA Accepts 52 Ambulatory Pediatrics 52 NUREG 52 EuroIntervention 52 Treating Depression 52 Arterial Hypertension 52 Clin J 52 GUIDELINES 52 Acquisition Proposal 52 Reference Document 52 Expert Panel 52 Substantiation 52 Statin Drugs 52 Initiative K DOQI 52 Unsolicited Proposal 52 Chronic Lyme Disease 52 Asthma Treatment 52 Discussion Paper 52 Liver Fibrosis 52 Audited Financials 52 Study Reinforces 52 FIND THIS STUDY 52 Total Coliform Rule 52 Hormone Therapy 52 Pregnancy Outcomes 52 Erythropoiesis Stimulating Agents ESAs 52 Epilepsia 52 Catheterization 52 #:#-# Abstract Free [005] 52 Aethlon Medical Releases 52 Files Amicus Brief 52 Node Positive 52 America HFSA 52 Reaccreditation 52 Acute Heart Failure 52 Orthostatic Hypotension 52 Nebulized Formoterol 52 Diagnostic Criteria 52 journal Infection Control 52 Pervasive Developmental Disorders 52 Less Invasive 52 See CLINICAL PHARMACOLOGY 52 Resurgex Plus 52 Teva Provides Update 52 Clinical Trial Evaluating 52 Parenteral Nutrition 52 Nasal Sprays 52 Antimicrobial Susceptibility Testing 52 Study Proves 52 Filing Requirements 52 Monograph 51 ANN INTERN MED 51 Submission Guidelines 51 #:# -# Abstract Free [001] 51 Aromatase Inhibitors 51 Final Determination 51 Invasive Fungal Infections 51 FINAL REPORT 51 Test Detects 51 Mercury Fillings 51 Practice Guidelines 51 #:# -# [005] 51 #:# -# Abstract Free [002] 51 Fat Grafting 51 Plaque Psoriasis 51 #:#-# Abstract Free [009] 51 Revised Guidelines 51 Reference Manual 51 Menopause Society NAMS 51 #:#-# Abstract Free [010] 51 Releases Findings 51 Cervical Spine 51 Clin Trials 51 Screening Tool 51 Therapeutic Targets 51 Issued Patent 51 Obtains Approval 51 Pharmacy AMCP 51 Arbitration Agreements 51 RECOMMENDS THAT 51 Programmatic Environmental Impact Statement 51 Rotavirus Vaccine 51 Fampridine SR NDA 51 Warning Letter 51 Cerebrovascular Diseases 51 Authorized Generics 51 Helping Smokers Quit 51 Carotid Artery Stenting 51 Exposure Drafts 51 Panel Mulls 51 Makes Recommendations 51 Combo Therapy 51 www.nejm.org 51 Skin Lesions 51 Bioidentical Hormones 51 CEQA Guidelines 51 Receives CE Marking 51 Epilepsy Drug 51 Receives Accreditation 51 Amicus Brief 51 Surgical Infections 51 Teacher Evaluations 51 Theratechnologies Announces 51 Restricts Access 51 Provides Guidance 51 Child Neurology 51 & Analgesia 51 Cases Involving 51 #:#-# [032] 51 Continuous Disclosure 51 Detection Evaluation 51 Pluripotent Stem Cells 51 NEJM.org 51 Comparative Effectiveness 51 CORPORATE DIRECTORY 51 GRI G3 51 Reasonable Accommodation 51 Reduced Risk 51 #:#-# Abstract Free [002] 51 Osteoporosis Treatment 51 Cervical Cancer Detection 51 Novel Antibiotic 51 OF STEFFANIE RIVERS 51 Quality Indicators 51 Applicant Guidebook 51 Proposed Legislation 51 Improving Patient Safety 51 Fact Sheets 51 Clinically Tested 51 journal Antimicrobial Agents 51 Condition Specific 51 Thematic Strategy 51 Appears Safe 51 Rotavirus Vaccines 51 Shingles Vaccine 51 ACGIH 51 DOSAGE AND ADMINISTRATION 51 GASB Issues 51 Draft SEIS 51 Cholesterol Lowering Drugs 51 Going Concern Qualification 51 JACC Cardiovascular Interventions 51 FDA Advisory Panel 51 Surgical Mesh 51 Diagnostic Tests 51 Index SPI SPIEX 51 #:#-# Abstract Free [006] 51 Welcomes Newest 51 Eligibility Requirements 51 Smallpox Vaccine 51 FDAAA 51 www.ecri.org 51 Pharmacopoeia USP 51 Tumor Response 51 Urgent Issues 51 e# e# [001] 51 Liver Toxicity 51 http:/www.ncbi.nlm.nih.gov/pubmed/# 51 Prohibited List 51 Clinical Outcome 51 #:#-# [035] 51 Association IBWA 51 Suppl. 51 Sustained Release 51 Clarification Regarding 51 R rosiglitazone maleate 51 FDA Approvable Letter 51 Eamonn Quigley 51 Ltd Therapeutic Competitors 51 Regains NASDAQ 51 Statement FEIS 51 CABG Surgery 51 Drug Shows Promise 51 Reply Brief 51 #:#-# [001] 51 Update Advisory MDKSA 51 Regulations Governing 51 Product Characteristics SmPC 51 Fondaparinux 51 Voluntary Consensus 51 BIOLASE Announces 51 Shareholder Meetings 51 Suicidality 51 Technical Specifications 51 Regulatory Filing 51 Cardiovascular Anesthesiologists 51 p.# [001] 51 FSMB 51 EMBO Molecular Medicine 51 Initiates Clinical Trial 51 ACR ARHP 50 Imaging Technique 50 Racial Disparities 50 Minimally Invasive Treatment 50 Informed Choices 50 Venous Thromboembolism 50 Gets FDA Clearance 50 number NCT# ClinicalTrials.gov 50 END FOOTNOTE 50 FDA Dermatologic 50 Completes Patient Enrollment 50 Gene Variants 50 Involuntary Exposure 50 Surgical Treatment 50 Favorable Ruling 50 ASGCT 50 NASDAQ Delisting 50 Psychiatry #:#-# [002] 50 Psychotropic Drugs 50 Amended Notice 50 Proton Pump Inhibitors 50 Reinforces Need 50 ANPRM 50 Molecular Mechanism 50 Alexco Announces 50 CNS Spectrums 50 Venous Thrombosis 50 Exposure Draft 50 Revised Guidance 50 Antitumor 50 Guides Concerning 50 Statutory Accounts 50 Lowers Risk 50 ICAEL 50 Levels Linked 50 Structured Finance Transactions 50 Ark. Sup 50 Powerful Tool 50 Law Takes Effect 50 Medicinal Chemistry Letters 50 Cancer Incidence Mortality 50 Receives Orphan Drug Designation 50 Drug Importation 50 Clinical Trial Enrollment 50 Conditional Approval 50 #:#-# Abstract Free [001] 50 Brain Wiring 50 drugs.com 50 Antipsychotic Drug 50 #:# -# [002] 50 Relieve Pain 50 Anemia Drugs 50 FDA Warns Against 50 Carotid Stenting 50 Adopts Revised 50 Patient Registry 50 Naturally Occurring 50 ASTM ISO 50 Arterial Disease 50 Medication Adherence 50 Pharmacopoeia 50 Protein Synthesis 50 Cancer Incidence 50 Regulatory Regime 50 Thrombolytic Therapy 50 Panel Endorses 50 Continuous Disclosure Policy 50 Regains Nasdaq 50 AdvaMed Code 50 theJournal 50 Asthma Medication 50 Outpatient Setting 50 Revised Recommendations 50 doi Abstract Free 50 Chronic Heart Failure 50 Unequal Treatment 50 Process Validation 50 Favorable Decision 50 Reduces Risk 50 Publicly Available 50 Epilepsy Drugs 50 Osteoporosis Drug 50 = document.location.protocol 50 FDA Approvals 50 Receives Approval From 50 Dry Powder Inhalers 50 Brain Stimulation 50 Consultation Paper 50 Prolongs Life 50 Total Hip Arthroplasty 50 WEB OF SCIENCE 50 Proves Effective 50 SEDAR www.SEDAR.com 50 Prevalence Worldwide 50 ADOPTION OF THE 50 Kidney Disease Outcomes 50 ASBMR 50 IND Application 50 journal Anesthesiology 50 Licenses Novel 50 Second Supplementary Bidder 50 Policies Procedures 50 Report DEIR 50 Anemia Drug 50 Underscores Importance 50 Shareholder Proposals 50 Plan CLUP 50 Seasonal Influenza 50 Rating Methodology 50 Electronic Submission 50 Medicinal Product 50 Nutrition Labels 50 Receives ONC ATCB 50 Ionizing Radiation 50 SUPPLEMENTARY INFORMATION 50 Pediatric Oncology Branch 50 Iron Deficiency Anemia 50 Gene Variation 50 Dispelling Myths 50 Aesthetic Surgery Journal 50 dual endothelin receptor antagonist 50 Fungal Infections 50 Vitamin D Deficiency 50 RESEARCH REPORT 50 Rhinosinusitis 50 Therapeutic Advances 50 Protein Linked 50 Study Validates 50 Combination Treatment 50 Laboratory Accreditation Program 50 Pain Medication 50 Half Yearly Report 50 Recognize Excellence 50 Expert Discusses 50 Treat Anemia 50 #:#-# Abstract Free [004] 50 NDA Submission 50 Study Casts Doubt 50 #nd Annual Meeting 50 Disease Models 50 Practitioner Guide 50 NASDAQ Deficiency Notice 50 Methylphenidate Transdermal System 50 NASDAQ Listing Requirements 50 Pharmacotherapy 50 ASCO GI 50 OR Live.com Presents 50 www.shire.com 50 Injectable Drug 50 Ohr Pharmaceutical Inc. 50 journal Biomacromolecules 50 Mammography Screening 50 Therapy Shows Promise 50 Corporate Governance Principles 50 Genetic Tests 50 Pharmacologic Treatment 50 Adverse Effects 50 Reconstitute 50 Gynecologic Cancers 50 Percutaneous Tibial Nerve Stimulation 50 Percutaneous Coronary Interventions 50 #:#-# [027] 50 Statement SEIS 50 Immune Mediated 50 Asthma Inhalers 50 Essential Element 50 Receives Complete Response 50 Coronary Revascularization 50 Frequently Asked Questions 50 Announces Effectiveness 50 Topical Treatment 50 Conceptual Framework 50 Blood Clotting 50 Pain Relievers 50 Preventing Cardiovascular Disease 50 Demonstrates Efficacy 50 Postmarketing 50 Supplementary Prospectus 50 Permanent Impairment 50 Severe Asthma 50 Cardiac Vascular 50 National Guideline Clearinghouse 49 Biomacromolecules 49 Shows Efficacy 49 Breast Exams 49 Receives Endorsement 49 Genetically Engineered Animals 49 Shelf Registration Statement 49 Obtains CE Mark 49 #:#-# [010] 49 NI #-# Preliminary Assessment 49 Ophthalmic Drugs Advisory 49 Granted Orphan Drug 49 Advises Caution 49 Unsolicited Offer 49 Artificial Organs 49 Directors Circular dated 49 Stent Placement 49 Journal Editors ICMJE 49 B.1 49 Postdoctoral Position 49 #:#-# [037] 49 Self Assessment Tool 49 Cervical Pathology 49 #:#-# [028] 49 Important Milestone 49 Renal Function 49 Certifications Commercial Items 49 BMC Musculoskeletal Disorders 49 Complies With 49 Gene Linked 49 Prescription Painkiller 49 Urinary Tract Infections 49 Risk Warning 49 Cites Flaws 49 Psychiatric Diagnosis 49 GHTF 49 Import Restrictions 49 Erythropoiesis Stimulating Agents 49 Interpretative Communication 49 Solicitation Number 49 Actions Taken 49 Clinical Lipidology 49 Risks Posed 49 Progenitor Cells 49 Patent Infringement Lawsuit 49 Pending Acquisition 49 PrimeSUITE ® 49 Demonstrates Significant 49 Medicines CSM 49 Injectable Fillers 49 Innovative Approaches 49 Monovalent Vaccine 49 Successfully Completes Phase 49 Announce Filing 49 Adjuvant Chemotherapy 49 Preconception 49 Files IND 49 Shareholders Approve Proposals 49 Material Fact 49 Statement dated 49 Supplementary Bidder Statement 49 Draft Programmatic Environmental Impact 49 Newly Revised 49 ANNUAL REPORT 49 Striking Balance 49 Demonstrates Sustained 49 Inhaled Nitric Oxide 49 Preclinical Data 49 Transatlantic Agenda 49 #:#-# [033] 49 www.thelancet.com 49 THRA 49 Catheter Associated 49 Study Raises Questions 49 Cochrane Database 49 Lawsuit Dismissed Against 49 FDA Panel Recommends 49 Molecular Basis 49 Executive Summary 49 #:#-#,# CrossRef 49 Ephedra Ban 49 Patentability 49 Receives NASDAQ 49 Accredits 49 Trans Fatty Acids 49 PMPRB 49 Conscience Clause 49 Archives Journals 49 Strongly Supports 49 Psychosocial Aspects 49 Ensure Compliance 49 Erythropoietic 49 Analytical Method 49 Merger Proposal 49 InvestorSoup 49 & Rheumatism journal 49 Greystar Resources Announces 49 Pain Medications 49 Carotid Endarterectomy 49 Appendix 4E 49 Pulmonary Arterial Hypertension 49 Long Term Efficacy 49 Advocates Urge 49 Desk Reference PDR 49 Jolina Proposal 49 Psoriasis Drug 49 Permanent Injunction Against 49 Incoterms ® 49 Appellate Panel 49 Increases Risk 49 Sleep Disturbances 49 Accounting Pronouncements 49 Workforce Shortage 49 Tobacco Smoke 49 Scoping Document 49 Aortic Dissection 49 COMPETITION COMMISSION 49 Childhood Trauma 49 Invites Nominations 49 Chronic Renal Failure 49 Antitrust Litig 49 Healthcare Professionals 49 Practice Recommendations 49 Improve Survival 49 Hematopoietic Stem Cell Transplantation 49 www.ncoa.org 49 BRUSSELS BELGIUM Marketwire #/#/# 49 Adverse Event 49 Panel Advises 49 Stem Cell Patents 49 Submits Application 49 #:#-# [014] 49 NexMed Receives 49 Viable Alternative 49 Vigorously Defend 49 Recommendation Statement 49 Experts Urge 49 Antipsychotic Drugs 49 Association AHPA 49 TBBPA 49 #:#-# [022] 49 Study Recommends 49 Bacteremia 49 Device Helps 49 STERIS Corporation Announces 49 Dietary Fat 49 Cost Effectiveness 49 Pharmaceutical Excipients 49 Biodegradable Polymers 49 FDA Cracks Down 49 Human Retroviruses 49 Explanatory Notes 49 Pandemic Influenza Vaccines 49 Sleep Duration 49 Stocktaking 49 Intravenous Formulation 49 Hr'g Tr 49 Pricing Supplement 49 Osteoporosis Drugs 49 Breast Carcinoma 49 Prescribing Information 49 @ Gowlings 49 What Constitutes 49 Clinical Trial Results 49 Prostate Cancer Treatment 49 Publicly Funded 49 Proves Successful 49 Total Hip Replacement 49 Vaccine Protects Against 49 Potential Impacts 49 Dietary Ingredients 49 Predictive Toxicology 49 MRSA Infections 49 Confirmatory Phase 49 NYSE Arca Listing 49 Hip Implants 49 Announces Revocation 49 Nonprofit Hospitals 49 http:/www.hematology.org 49 Surgical Techniques 49 Voluntary Withdrawal 49 Reporting Requirements 49 Inhaled Steroids 49 External Defibrillators 49 Redesigns Website 49 Drug Candidate 49 Menopausal Symptoms 49 Coronary Angiography 49 Knee Implant 49 JNCCN 49 Outlines Priorities 49 Taps Lobbyist 49 Performers List 49 Biological Therapy 49 Hormone Replacement 49 Endocrine Society Journal 49 www.ama assn.org 49 NQF endorsed 49 Crit Rev 49 MVEIRB 49 Systemic Delivery 49 Selection Criteria 49 Appendix VII 49 Prenatal Exposure 49 Mitigation Strategies 49 Misleading Claims 49 Bone Metabolism 49 Option Grants 49 NCCN Guidelines ™ 49 Functional Outcomes 49 Disclosure Requirements 49 Urinary Catheter 49 Resource Calculation 49 Environ Health Perspect 49 Listing Application 49 Susceptibility Testing 49 Unsolicited Tender Offer 49 Quarterly Report Announcement 49 Electromagnetic Fields 49 J Nutr 49 www.nccn.org 49 Vaginal Infections 49 Nasdaq Delisting 49 Dr. Gott Compelling 49 journal Gynecologic Oncology 49 Report Sheds Light 49 Zero Tolerance Policy 49 Receives Unsolicited 49 Eur J Cancer 49 www.pranabio.com 49 Procedural Rules 49 www.elekta.com 49 Antiviral Drug 49 Rat Poison Found 49 Antibiotic Use 49 LEGAL NOTICE 49 #/#/EEC [001] 49 Psychological Effects 49 Panel Examines 49 Patients Undergoing 49 Seeks Input 49 Evid 49 Circular dated 49 Attitudes Towards 49 Racial Disparity 49 PCPZ 49 Constituency Delimitation Commission 49 Receives Approvable Letter 49 Endocrine Disruptors 49 JUPITER Justification 49 www.themedicinescompany.com 49 Diagnosis Treatment 49 Recent Accounting Pronouncements 49 Summary Judgment Order 49 Pneumococcal Disease 49 #:#-# Abstract Free [007] 48 Preterm Delivery 48 Considers Easing 48 RoHS Compliance 48 e# e# [003] 48 Decision #/#/EC 48 Statistical Methods 48 Commission Decision #/#/EC 48 Xenotransplantation 48 www.dh.gov.uk 48 CICA Accounting Guideline 48 Revised Proposal 48 Amending Directive 48 First Trimester 48 Helps Identify 48 rhLF 48 Food Labelling 48 Ortho Dermatologics 48 MMR Vaccine 48 ABLAVAR ® 48 Antidepressant Treatment 48 Treating Heart Failure 48 Efficacy Study 48 Wound Closure 48 Enteral Nutrition 48 Substantially Reduce 48 Data Indicate 48 Critical Reviews 48 Antidumping Duties 48 Poorly Controlled 48 TB Vaccine 48 Testosterone Patch 48 #:#-# [029] 48 Seminar Focuses 48 Stockholder Vote 48 Mortality Weekly Report MMWR 48 Chronic Kidney 48 proposed rulemaking NPRM 48 www.astm.org 48 Files Definitive Proxy 48 Weight Loss Drug 48 Hidden Epidemic 48 NOPR 48 Factsheet 48 Memorandum Opinion 48 Cardiovascular Intervention 48 Rheumatoid 48 Stem Cell Treatment 48 Chemical Substances 48 Accelerated Approval 48 Circulation Cardiovascular Genetics 48 User Requirements 48 Trademark Litigation 48 DOR BioPharma Announces 48 Growing Importance 48 Fibromyalgia Pain 48 Same Sex Relationships 48 Sign Licensing Agreement 48 Lower Blood Pressure 48 Cognitive Impairment 48 Eur Urol 48 Hedging Relationships 48 Reduce Risk 48 Artificial Cornea 48 Pract 48 First Patient Treated 48 Notified Bodies 48 Meningococcal Disease 48 doi #.#/S#-# 48 www.annals.org 48 Submits IND 48 PMA Supplement 48 ACIP recommendations 48 Tissue Engineered 48 www.acc.org 48 Proxy Disclosure 48 Homeopathic Pharmacopoeia 48 Antiviral Agents 48 Breast Implant 48 AQUARIUS PLATINUM LIMITED 48 Corrective Actions 48 Occupational Exposure 48 Alternative Medicines 48 Regulatory Requirements 48 EFSA GMO Panel 48 Seeks Nominations 48 Antiviral Drugs 48 AHA Guidelines 48 Hospital Acquired Pneumonia 48 Directive #/#/EC [004] 48 Illicit Drug Use 48 Perinatal Care 48 Cognitive Functioning 48 Prognostic Factors 48 Submits Supplemental 48 PROCEDURES 48 AFEP MEDEF 48 Phasing Out 48 Post Menopausal 48 Voluntarily Withdraws 48 Mortality Risk 48 Flagstone Re Announces 48 Applauds Passage 48 CACG 48 Hidden Danger 48 IASC Foundation 48 Diabetic Foot Care 48 FORWARDED 48 #.#-# [033] 48 Corporate Governance Statement 48 #.#-# Offeror Representations 48 Safe Medication 48 OHRP 48 Initiates Enrollment 48 Study Analyzes 48 Contraindications 48 please email scr@zacks.com 48 Flamel Technologies Announces 48 Transdermal Drug 48 Regulatory Submissions 48 AAVMC 48 Cholesterol Lowering Drug 48 Receives Favorable Ruling 48 Resp 48 EFSA Panel 48 Stockholders Reject 48 Patent Infringement Litigation 48 Stem Cell Treatments 48 Play Crucial Role 48 Anti Infective 48 Docosahexaenoic Acid 48 Receives Fast Track 48 Myocardial Perfusion Imaging 48 NIH Consensus 48 Impact Assessments 48 Cardiovascular Radiology 48 AOSSM 48 Accreditation Program 48 RELEASE FROM 48 Appendix B 48 Upcoming Deadline 48 Formularies 48 Genetically Engineered Foods 48 Datasheet 48 Improves Outcomes 48 Actuarial Standards 48 Neurological Devices 48 Urinary Incontinence 48 Boxed Warning 48 Directive #/#/EEC [001] 48 Subsidiary Files 48 SPJ Code 48 Lung Cancer Drug 48 Association AIHA 48 Thromb Haemost 48 WCRF AICR 48 Strongly Linked 48 Survey MEPS 48 Am J Clin 48 #/#/EEC [002] 48 Spinal Disc 48 Genmab Annual Report 48 FOIA Requests 48 Unusual Activity 48 #.#.#.# [011] 48 Helps Detect 48 XPEL Announces 48 Earns Accreditation 48 EFFECTIVE DATE 48 Genetic Predisposition 48 Functioning Disability